Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study

Blood (2024) 144 (Supplement 1): 338.

https://doi.org/10.1182/blood-2024-199868

Published: 2024

Journal Articles

Long-Term Follow-up of Patients with Aplastic Anemia Enrolled in Phase 2/3 Trials of Immunosuppressive Therapy Plus Romiplostim As a First-Line Treatment: Two-Year Interim Analysis

Blood (2024) 144 (Supplement 1): 1310.

https://doi.org/10.1182/blood-2024-193925

Published: 2024

Journal Articles

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Blood (2023) 142 (Supplement 1): 626.

https://doi.org/10.1182/blood-2023-180164

Published: 2023

Journal Articles

Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)

Blood (2022) 140 (Supplement 1): 3718–3720.

https://doi.org/10.1182/blood-2022-157006

Published: 2022

Journal Articles

Dual Targeting of Cell-Cycle Checkpoint Kinase and Unfolded Protein Response As a Novel Therapeutic Approach for High-Risk Multiple Myeloma with TP53 Deletion or Mutations

Yuka Tanaka, MD, Takayuki Tabayashi, MD PhD, Yasuyuki Takahashi, MD PhD, Yuta Kimura, MD, Tatsuki Tomikawa, MD PhD, Junichi Watanabe, MD PhD, Tomoe Anan-Nemoto, MD PhD, Morihiko Sagawa, MD PhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, Masahiro Kizaki, MD PhD

Blood (2018) 132 (Supplement 1): 5613.

https://doi.org/10.1182/blood-2018-99-116247

Published: 2018

Journal Articles

CD14-CD15+, Possible Cells Are Potent Myeloid-Derived Suppressor Cells, Which Affect the Pathogenesis of Induction and Regression in Methotrexate-Mediated Lymphoproliferative Disorders

Michihide Tokuhira, MD PhD, Shuntaro Saito, MD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Tomoe Anan, MD, PhD, Shuji Momose, MD PhD, Morihiro Higashi, MD, PhD, Takayuki Shimizu, MD PhD, Takehiko Mori, MD PhD, Takayuki Tabayashi, MD PhD, Reiko Watanabe, MD PhD, Jun-ichi Tamaru, MD, PhD, Shinichiro Okamoto, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 2946.

https://doi.org/10.1182/blood.V128.22.2946.2946

Published: 2016

Journal Articles

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

Takayuki Tabayashi, MD PhD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Morihiko Sagawa, MD PhD, Tomoe Anan-Nemoto, MDPhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 3256.

https://doi.org/10.1182/blood.V128.22.3256.3256

Published: 2016

Journal Articles

Novel Therapeutic Approach to Overcome Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma By Targeting TOPK/PBK

Takayuki Tabayashi, MD PhD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Tomoe Nemoto-Anan, MD PhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, MD PhD, Masahiro Kizaki, MD PhD

Blood (2015) 126 (23): 1763.

https://doi.org/10.1182/blood.V126.23.1763.1763

Published: 2015

Journal Articles

Targeting the Wnt/β-Catenin Signaling Pathway in Multiple Myeloma: A Possible New Therapeutic Approach to Overcome Bortezomib-Resistance

Takayuki Tabayashi, MD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Morihiko Sagawa, MD PhD, Tomoe Nemoto, MD, Reiko Watanabe, MD PhD, Michihide Tokuhira, MD, Shigehisa Mori, MD, Masahiro Kizaki, MD

Blood (2014) 124 (21): 3372.

https://doi.org/10.1182/blood.V124.21.3372.3372

Published: 2014

Journal Articles

Successful Management of Transplant-Ineligible Patients with Refractory/Relapsed Multiple Myeloma By Using a Biweekly or Longer Modified Bortezomib Schedule As Interval Maintenance therapy

Michihide Tokuhira, MD PhD, Yuta Kimura, MD, Tatsuki Tomikawa, Yasuyuki Takahashi, Morihiko Sagawa, MD PhD, Tomoe Nemoto, MD, Takayuki Tabayashi, MD PhD, Reiko Watanabe, MD PhD, Masahiro Kizaki, MD PhD

Blood (2014) 124 (21): 5758.

https://doi.org/10.1182/blood.V124.21.5758.5758

Published: 2014

Journal Articles

TM-233 Exerts Anti-Myeloma Activity and Overcomes Bortezomib-Resistance In Human Multiple Myeloma Cells By Targeting NF-κB and JAK/STAT Dual-Signaling Pathways

Morihiko Sagawa, MD, PhD, Tatsuki Tomikawa, MD, Tomoe Anan, MD, Takayuki Tabayashi, MD, PhD, Reiko Watanabe, MD, PhD, Michihide Tokuhira, MD, PhD, Masaki Ri, MD, PhD, Yuichi Hashimoto, PhD, Shinsuke Iida, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2013) 122 (21): 4427.

https://doi.org/10.1182/blood.V122.21.4427.4427

Published: 2013

Journal Articles

Adaptor Protein Lnk Binds to and Inhibits Normal and Leukemic FLT3

Dechen Lin, PhD, Tong Yin, MD, PhD, Maya koren-Michowitz, MD, Ling-Wen Ding, Saskia Gueller, MD, Sigal Gery, PhD, Takayuki Tabayashi, MD, Ulla Bergholz, Julhash Kazi, Lars Rönnstrand, PhD, Carol Stocking, Phillip Koeffler, MD

Blood (2012) 120 (21): 1312.

https://doi.org/10.1182/blood.V120.21.1312.1312

Published: 2012

Journal Articles

TM-233, a Novel Analog of 1'-Acetoxychavicol Acetate (ACA), Induces Cell Death in Human Myeloma Cells by Inhibiting Both JAK/STAT and NF-κB Pathways: A Possible New Agent for Overcoming Bortezomib-Resistance.

Morihiko Sagawa, MD, PhD, Tatsuki Tomikawa, MD, Tomoe Nemoto, MD, Takayuki Tabayashi, MD, PhD, Reiko Watanabe, MD, PhD, Michihide Tokuhira, MD, PhD, Masaki Ri, MD, PhD, Yuichi Hashimoto, PhD, Shinsuke Iida, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2012) 120 (21): 2939.

https://doi.org/10.1182/blood.V120.21.2939.2939

Published: 2012

Journal Articles

Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3

De-Chen Lin, Tong Yin, Maya Koren-Michowitz, Ling-Wen Ding, Saskia Gueller, Sigal Gery, Takayuki Tabayashi, Ulla Bergholz, Julhash U. Kazi, Lars Rönnstrand, Carol Stocking, H. Phillip Koeffler

Blood (2012) 120 (16): 3310–3317.

https://doi.org/10.1182/blood-2011-10-388611

Published: 2012

Includes: Supplemental data

Journal Articles

Adaptor Protein LNK Binds to and Is Phosphorylated by JAK3 and May Serve as a Scaffold for JAK3 Autophosphorylation In the Absence of An Appropriate Cytokine Receptor

Maya koren-Michowitz, MD, Sigal Gery, PhD, Daniel Nowak, MD, Arnon Nagler, M.D., Aiko Matsubara, MS, Takayuki Tabayashi, MD, PhD, Seishi Ogawa, MD, PhD, H. Phillip Koeffler, MD

Blood (2010) 116 (21): 2785.

https://doi.org/10.1182/blood.V116.21.2785.2785

Published: 2010

Journal Articles

Adaptor Protein Lnk Negatively Regulates Bcr-Abl-Induced Cell Proliferation through Inhibition of the Stat5 Signaling Pathway.

Takayuki Tabayashi, MD, Sigal Gery, PhD, Maya Koren-Michowitz, MD, H.Phillip Koeffler, MD

Blood (2010) 116 (21): 3406.

https://doi.org/10.1182/blood.V116.21.3406.3406

Published: 2010

Journal Articles

Evolution of Rituximab as “Standard” Therapy in Patients (pts) with Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) in Japan: An Analysis from West-Japan Hematology/Oncology Group (West-JHOG) NHL Outcomes Project.

Blood (2006) 108 (11): 4698.

https://doi.org/10.1182/blood.V108.11.4698.4698

Published: 2006

Journal Articles

Minimal Residual Disease Detection by Real Time PCR of the Dominant-Negative Isoform of Ikaros in Patients with Acute Lymphoblastic Leukemia.

Takayuki Tabayashi, MD, Fumihiko Ishimaru, MD, Koichi Nakase, MD, Hiromi Nakashima, Itaru Kataoka, MD, Mitsune Tanimoto, MD

Blood (2006) 108 (11): 4416.

https://doi.org/10.1182/blood.V108.11.4416.4416

Published: 2006

NARROW

Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study

Long-Term Follow-up of Patients with Aplastic Anemia Enrolled in Phase 2/3 Trials of Immunosuppressive Therapy Plus Romiplostim As a First-Line Treatment: Two-Year Interim Analysis

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)

Dual Targeting of Cell-Cycle Checkpoint Kinase and Unfolded Protein Response As a Novel Therapeutic Approach for High-Risk Multiple Myeloma with TP53 Deletion or Mutations

CD14-CD15+, Possible Cells Are Potent Myeloid-Derived Suppressor Cells, Which Affect the Pathogenesis of Induction and Regression in Methotrexate-Mediated Lymphoproliferative Disorders

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

Novel Therapeutic Approach to Overcome Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma By Targeting TOPK/PBK

Targeting the Wnt/β-Catenin Signaling Pathway in Multiple Myeloma: A Possible New Therapeutic Approach to Overcome Bortezomib-Resistance

Successful Management of Transplant-Ineligible Patients with Refractory/Relapsed Multiple Myeloma By Using a Biweekly or Longer Modified Bortezomib Schedule As Interval Maintenance therapy

TM-233 Exerts Anti-Myeloma Activity and Overcomes Bortezomib-Resistance In Human Multiple Myeloma Cells By Targeting NF-κB and JAK/STAT Dual-Signaling Pathways

Adaptor Protein Lnk Binds to and Inhibits Normal and Leukemic FLT3

TM-233, a Novel Analog of 1'-Acetoxychavicol Acetate (ACA), Induces Cell Death in Human Myeloma Cells by Inhibiting Both JAK/STAT and NF-κB Pathways: A Possible New Agent for Overcoming Bortezomib-Resistance.

Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3

Adaptor Protein LNK Binds to and Is Phosphorylated by JAK3 and May Serve as a Scaffold for JAK3 Autophosphorylation In the Absence of An Appropriate Cytokine Receptor

Adaptor Protein Lnk Negatively Regulates Bcr-Abl-Induced Cell Proliferation through Inhibition of the Stat5 Signaling Pathway.

Evolution of Rituximab as “Standard” Therapy in Patients (pts) with Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) in Japan: An Analysis from West-Japan Hematology/Oncology Group (West-JHOG) NHL Outcomes Project.

Minimal Residual Disease Detection by Real Time PCR of the Dominant-Negative Isoform of Ikaros in Patients with Acute Lymphoblastic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only